We selected the level of CRP as a biomarker to measure the effect size of TNF inhibition on the risk of colorectal cancer, instead of the level of TNFR1, based on previously published literature (Kang et al., 2021, 2022). The gene discussed is CRP; the disease is colorectal cancer.